Real-world evidence
Submitted by Anonymous (not verified) on 1 August 2024 - 10:11
Real-world evidence
Infosheet: EMA review of real-world data studies
Submitted by Anonymous (not verified) on 1 August 2024 - 10:10
Infosheet: EMA review of real-world data studies
Real-world evidence framework to support EU regulatory decision-making: 2nd report on the experience gained with regulator-led studies from February 2023 to February 2024
Submitted by Anonymous (not verified) on 1 August 2024 - 9:55
Real-world evidence framework to support EU regulatory decision-making: 2nd report on the experience gained with regulator-led studies from February 2023 to February 2024
Antimicrobial Sales and Use (ASU) Platform: Release notes
Submitted by Anonymous (not verified) on 1 August 2024 - 8:54
Antimicrobial Sales and Use (ASU) Platform: Release notes
Surgiflo haemostatic matrix kit - Ferrosan - Procedural steps and scientific information after initial consultation
Submitted by Anonymous (not verified) on 30 July 2024 - 15:20
Surgiflo haemostatic matrix kit - Ferrosan - Procedural steps and scientific information after initial consultation
Release notes - production release version 1.7.2427- 30 July 2024 - Veterinary Medical Products Regulation: Union Product Database
Submitted by Anonymous (not verified) on 30 July 2024 - 14:52
Release notes - production release version 1.7.2427- 30 July 2024 - Veterinary Medical Products Regulation: Union Product Database
Human medicines European public assessment report (EPAR): VidPrevtyn Beta, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 10/11/2022, Revision: 4, Status: Withdrawn (authorisation)
Submitted by Anonymous (not verified) on 30 July 2024 - 13:31
Human medicines European public assessment report (EPAR): VidPrevtyn Beta, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 10/11/2022, Revision: 4, Status: Withdrawn (authorisation)
VidPrevtyn Beta: Periodic safety update report assessment 10 May 2023 to 9 November 2023
Submitted by Anonymous (not verified) on 30 July 2024 - 13:27
VidPrevtyn Beta: Periodic safety update report assessment 10 May 2023 to 9 November 2023
Extraordinary meeting of the Committee for Medicinal Products for Human Use (CHMP): 29 July 2024, Online, European Medicines Agency, Amsterdam, the Netherlands, from 29 July 2024, 10:00 (CEST) to 29 July 2024, 12:00 (CEST)
Submitted by Anonymous (not verified) on 30 July 2024 - 13:00
Extraordinary meeting of the Committee for Medicinal Products for Human Use (CHMP): 29 July 2024, Online, European Medicines Agency, Amsterdam, the Netherlands, from 29 July 2024, 10:00 (CEST) to 29 July 2024, 12:00 (CEST)
Human medicines European public assessment report (EPAR): Upstelda, ustekinumab, Status: Withdrawn application (before opinion)
Submitted by Anonymous (not verified) on 30 July 2024 - 12:50
Human medicines European public assessment report (EPAR): Upstelda, ustekinumab, Status: Withdrawn application (before opinion)